A nine-gene transcriptional signature derived from Niche 9 was associated with atezolizumab-plus-bevacizumab response, enhanced lymphoid immune features, lower Tumour Immune Dysfunction and Exclusion scores, and favourable clinical outcomes in independent cohorts.
Abstract
Background: Atezolizumab plus bevacizumab is a first-line therapy for advanced hepatocellular carcinoma (HCC), yet only a subset of patients achieve durable benefit. The spatial organization of the tumour microenvironment (TME) and its relationship to immunotherapy response remain incompletely understood. Methods: We integrated single-cell transcriptomics, spatial transcriptomics, spatial proteomics, and bulk RNA-sequencing cohorts to characterize spatially organized immune ecosystems associated with immunotherapy response in HCC. Single-cell RNA sequencing from 100 HCC samples was used to construct a cellular reference, which was integrated with spatial transcriptomics from 12 sections to identify nine consensus spatial niches. Results: Niche 9 represented a lymphoid-enriched immune state characterized by B cells, plasma cells, natural killer cells, T-cell subsets, macrophages, and tertiary lymphoid structure-associated transcriptional features. Independent validation in a pretreatment, response-annotated Visium cohort showed enrichment of Niche 9-associated transcriptional activity in immunotherapy responders, while spatially co-registered 51-plex CODEX profiling provided orthogonal protein-level support for its lymphoid and immune-enriched phenotype. Multi-omics characterization further revealed coordinated immune-cell localization, ligand–receptor-associated patterns, and distinct metabolic programmes, with MEI1-positive plasma cells displaying enhanced secretory and stress-adaptation states. A nine-gene transcriptional signature derived from Niche 9 was associated with atezolizumab-plus-bevacizumab response, enhanced lymphoid immune features, lower Tumour Immune Dysfunction and Exclusion scores, and favourable clinical outcomes in independent cohorts. Conclusions: These multi-cohort and multi-omics analyses define a spatially derived lymphoid-enriched immune programme and link its molecular features to immunotherapy sensitivity in HCC.
It is shown that spatial CD8+ T-cell exclusion is associated with lower objective response rates and shorter progression-free survival in ICB-treated NSCLC patients, and further evaluation of spatial immune contexture as a complementary biomarker in ICB-treated patients is supported.
J. Guégan, B. Bonhomme, F. Peyraud et al.· Signal Transduction and Targ...· 0 citations
The hypothesis-generating findings suggest that spatial coordination topology is associated with the immunotherapy response in HCC and provide a principled graph-based framework for developing and evaluating future spatial biomarkers.
P. Mittal, J. Chauhan, Deepu Philip et al.· Scientific Reports· 0 citations
The mechanisms through which malignant, myeloid, lymphoid, endothelial, and stromal populations interact across spatial niches are discussed, and how these maps can inform biomarker discovery, patient stratification, and rational combination therapy are examined.
Prospective studies should use standardized, spatially resolved, and longitudinal biomarker panels to enrich trials, distinguish prognostic from predictive effects, and adapt therapy when immune exclusion or antigen escape emerges, as well as define a practical framework for biomarker-guided immunotherapy.
This review synthesizes recent advances in spatial biology that support a shift from counting TLSs to interpreting them as spatially organized immune microenvironmental units embedded within local tumor ecosystems and outlines a staged, module-matched composite biomarker workflow combining digital pathology, targeted m...
Xu-Chen Wang, Lin Lin· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.